TICKERNERD
Menu
CATXCATXHealthcare · Medical Devices

CATX Stock Forecast: Perspective Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.81
+1.44% on the day

The 15 Wall Street analysts covering Perspective Therapeutics, Inc. hold a median 12-month price target of $13 — +362.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$320.8M
Ticker Nerd rank
30 / 100
Median analyst target
$13
Analysts covering
15
Revenue$0.0
Operating income−$29.3M
Net income−$26.8M
Free cash flow−$34.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.9%
1M
−11.6%
YTD
+2.2%
1Y
−16.9%
From 52W high
−50.3%
From 52W low
+37.1%
$2.05
$5.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CATX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Perspective Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
71
Size
60
Quality
59
Volatility
53
Value
37
Accruals
36
Momentum
30
Growth
20
Issuance
18

Revisions (71): Analysts have, on balance, been raising their forecasts.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CATX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CATX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26CATXHigh $18Median $13Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $5Median $13High $18

The green dot is the last close — the median target sits +362.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Aug 2026BMO CapitalInitiatesOutperform—
14 Aug 2026B of A SecuritiesMaintainsNeutral—
11 Aug 2026Piper SandlerMaintainsOverweight—
5 May 2026BTIGReiteratesBuy—
5 May 2026WedbushReiteratesOutperform—
20 Apr 2026WedbushReiteratesOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
18 Mar 2026B. Riley SecuritiesMaintainsBuy—
18 Mar 2026UBSMaintainsBuy—
18 Mar 2026WedbushReiteratesOutperform—
17 Mar 2026BTIGReiteratesBuy—
17 Mar 2026RBC CapitalMaintainsOutperform—
19 Feb 2026Piper SandlerInitiatesOverweight—
30 Jan 2026HC Wainwright & Co.MaintainsBuy—
30 Jan 2026WedbushReiteratesOutperform—
13 Jan 2026BTIGReiteratesBuy—
21 Nov 2025UBSMaintainsBuy—
18 Nov 2025B. Riley SecuritiesMaintainsBuy—
13 Oct 2025BTIGReiteratesBuy—
10 Oct 2025BTIGInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CATX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CATX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Perspective Therapeutics, Inc. returned −16.9% against +17.5% for the S&P 500, dividends included.

CATX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Oct 25Jan 26Apr 26Jul 26CATXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CATX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Perspective Therapeutics, Inc. (CATX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 85% of US stocks

Price / sales
784.3×

Cheaper than 1% of US stocks

Price / book
1.0×

Cheaper than 73% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−72.1%

Higher than 3% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−36121.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.6%

Higher than 24% of US stocks

Return on assets
−22.3%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Perspective Therapeutics, Inc. (CATX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Perspective Therapeutics, Inc. has a market value of $320.8M and an enterprise value of $87.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 72.1% year on year.

  • Net income over the same four quarters: −$116.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$121.2M.

  • Shares outstanding: 114.1M.

  • Trailing P/E: −2.0×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Perspective Therapeutics, Inc. employs 163 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

CATX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CATXPerspective Therapeutics, Inc.$320.8M
30
CVCapsoVision, Inc.$328.9M
20
MOBIMobia Medical, Inc.$331.2M
2
VMDViemed Healthcare, Inc.$334.2M
93
RCELAVITA Medical, Inc.$301.3M
66
OFIXOrthofix Medical, Inc.$353.6M
80
TMCITreace Medical Concepts, Inc.$287.4M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Perspective Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CATX news & analysis

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

GlobeNewsWire · 14 Sept 2026positive

Perspective Therapeutics announced a clinical trial collaboration and supply agreement with Merck to evaluate its radiopharmaceutical [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors. The collaboration is part of Perspective's work as a radiopharmaceutical development company advancing cancer treatments.

Why it matters — A CATX watcher would care because the agreement with Merck lends external validation and potential development support for Perspective's lead investigational radiopharmaceutical candidate in combination with a widely used immunotherapy.

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

GlobeNewsWire · 11 Sept 2026positive

Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET radiopharmaceutical program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium 2026, scheduled for November 18-20, 2026 in Barcelona, Spain. The conference plans to release further abstract details on November 4, 2026.

Why it matters — Presentation of updated VMT-α-NET data at a major international oncology conference highlights progress in one of the company's key clinical programs and brings its findings to broader scientific attention.

Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans

Seeking Alpha · 1 Sept 2026positive

RBC analyst/Seeking Alpha coverage keeps a "Strong Buy" rating on Perspective Therapeutics, citing durable clinical data and near-term catalysts across its radiopharmaceutical pipeline. The company plans pivotal Phase 3 initiation for bamzireotide navoxetan in SSTR2-expressing NETs for late 2026, with upcoming data readouts for NET and melanoma programs.

Why it matters — A CATX watcher would care because the item points to a positive outlook tied to upcoming data readouts and Phase 3 plans that could represent inflection points for the company.

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

Zacks Investment Research · 4 Aug 2026neutral

A Zacks Research article examines how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year, asking whether medical stocks are lagging CATX.

Why it matters — CATX watchers would care because it shows how the company's year-to-date performance compares with its sector and peer Bristol Myers Squibb.

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zacks Investment Research · 3 Aug 2026neutral

Zacks reports that the medical sector's earnings season is off to a strong start, and it identifies four biotech companies as positioned to potentially beat estimates in their upcoming quarterly results. The excerpt does not name which four companies are highlighted.

Why it matters — CATX watchers may note a positive earnings environment in the biotech sector, though it is unclear from this report whether Perspective Therapeutics is among the four companies mentioned.

FAQ

Frequently asked questions about CATX stock

What is the CATX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Perspective Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $5 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CATX stock a buy right now?

Of the 15 analysts covering Perspective Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perspective Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CATX?

As at 12 Sept 2026, Perspective Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (71 of 100).

Will CATX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +362.6% from the last close, and Ticker Nerd's factor model ranks Perspective Therapeutics, Inc. 30 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CATX stock forecast for 2030?

No analyst covering Perspective Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CATX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $18 over the next 12 months.

How has CATX stock performed over the past year?

Perspective Therapeutics, Inc. returned -16.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Perspective Therapeutics, Inc. do?

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer.

What is the latest news on CATX?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors". Perspective Therapeutics announced a clinical trial collaboration and supply agreement with Merck to evaluate its radiopharmaceutical [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors. The collaboration is part of Perspective's work as a radiopharmaceutical development company advancing cancer treatments.

Company

About Perspective Therapeutics, Inc.

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.

CEO Mr. Johan M. Spoor · 163 employees · United States · https://www.perspectivetherapeutics.com